A highly selective 1,2-dihydroquinoxaline derivative as a potent PRMT5-MTA complex inhibitor
{{output}}
Protein arginine methyltransferase 5 (PRMT5) is a promising therapeutic target in oncology. However, first-generation PRMT5 inhibitors failed in clinical trials due to dose-limiting hematologic toxicity, likely resulting from non-selective inhibition of PRMT5 ... ...
